Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 115

Sort by

Sort Order Select

Journal Articles

The Well Tolerated VA-Based Regimen Bringing to High Quality of Life Did Not Absolutely Inferior to Intensive Chemotherapy in AML Patients with NPM1 Mutation

Wenbing Duan, Qi Chen, WenJing Yu, Jinsong Jia, Jing Wang, Xiaolu Zhu, Ting Zhao, Qian Jiang, Guorui Ruan, Xiaosu Zhao, Hongxia Shi, Ying-Jun Chang, Yu Wang, Lanping Xu, Xiaohui Zhang, Xiaojun Huang, Hao Jiang

Blood (2024) 144 (Supplement 1): 5952.

https://doi.org/10.1182/blood-2024-206400

Published: 2024

Journal Articles

Bone Marrow Endothelial Progenitor Cells Are Involved in Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Shunjie Yu, Mengyao Yuan, Mei Bao, Xiaoshuai Zhang, Qian Jiang

Blood (2024) 144 (Supplement 1): 6580.

https://doi.org/10.1182/blood-2024-205015

Published: 2024

Journal Articles

Ponatinib 2-Year Efficacy, Safety and Health-Related Quality of Life in Patients with Philadelphia Chromosome-Positive Leukemia: An Open-Label, Multicenter, Phase 2 Clinical Trial in China

Blood (2024) 144 (Supplement 1): 6602.

https://doi.org/10.1182/blood-2024-208258

Published: 2024

Journal Articles

Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with CSF3R T618I : A Multi-Centre Retrospective Study

Blood (2024) 144 (Supplement 1): 1793.

https://doi.org/10.1182/blood-2024-207591

Published: 2024

Journal Articles

Sex Differences in Disease Characteristics and Outcome in Adults with Acute Myeloid Leukemia from China

Zongru Li, Lu Yu, Li-Juan Hu, Ting Zhao, Wenbing Duan, Jing Wang, Jinsong Jia, Jing Liu, Ya-Zhen Qin, Hao Jiang, Xiaohui Zhang, Feifei Tang, Yuqian Sun, XiaoDong Mo, Lanping Xu, Yu Wang, Xiaojun Huang, Qian Jiang

Blood (2024) 144 (Supplement 1): 6121.

https://doi.org/10.1182/blood-2024-211874

Published: 2024

Journal Articles

Clinical and Molecular Predictors of Response and Survival Following Venetoclax Plus Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia

Lin-Ya Wang, Feifei Tang, Xiao-Jun Huang, Hai-Tao Gao, Qiang Fu, Qian Jiang, Hao Jiang, Yu Wang, Lan-Ping Xu, Xiaohui Zhang

Blood (2024) 144 (Supplement 1): 6067.

https://doi.org/10.1182/blood-2024-202795

Published: 2024

Journal Articles

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Blood (2024) 144 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2024-202790

Published: 2024

Journal Articles

Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China

Blood (2024) 144 (Supplement 1): 1767.

https://doi.org/10.1182/blood-2024-206453

Published: 2024

Journal Articles

Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

Qian Jiang, Li Weiming, Yanli Zhang, Qiang Wang, Suning Chen, Bingcheng Liu, Zhuogang Liu, Jie Jin, Zhenfang Liu, Jianyu Weng, Xin Du, Xielan Zhao, Li Meng, Lie Lin, Wanlin Ye, Shujie Yan, Yihan Wang, Jingrong Cao

Blood (2024) 144 (Supplement 1): 477.

https://doi.org/10.1182/blood-2024-205300

Published: 2024

Journal Articles

Genetic Abnormalities Associated with Outcomes in Unfit Patients with Acute Myeloid Leukemia Receiving Less Intensive Therapy in the Real World

Lu Yu, Lijuan Hu, Zongru Li, Ting Zhao, Wenbing Duan, Jing Wang, JinSong Jia, Jing Liu, Ya-Zhen Qin, Hao Jiang, Xiaohui Zhang, Feifei Tang, Yuqian Sun, XiaoDong Mo, LanPing Xu, Yu Wang, Xiaojun Huang, Qian Jiang

Blood (2024) 144 (Supplement 1): 1537.

https://doi.org/10.1182/blood-2024-207269

Published: 2024

Journal Articles

Blinatumomab Combined with Venetoclax Increasing the Abundance of CD8 T Cell and NK Cell and Improve the Outcome in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients

Lijuan Hu, Ya-Zhe Wang, Xiang Wang, Zongru Li, Ting Zhao, Wenbing Duan, Lu Yu, Qian Jiang

Blood (2024) 144 (Supplement 1): 2815.

https://doi.org/10.1182/blood-2024-211905

Published: 2024

Journal Articles

Clinical Features and Prognostic Nomogram for Therapy-Related Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Menglin Li, Yi-Meng Li, Qingyuan Qu, Yuxiu Chen, Jianying Zhou, Mengyu Xiao, Chencong Wang, Qi Chen, Xiaolu Zhu, Yun He, YuanYuan Zhang, Qian Jiang, Hao Jiang, Jin Lu, YingJun Chang, Xiaosu Zhao, Xiangyu Zhao, Xiao Jun Huang, Xiaohui Zhang

Blood (2024) 144 (Supplement 1): 1486.

https://doi.org/10.1182/blood-2024-204777

Published: 2024

Journal Articles

The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

Zongru Li, Lu Yu, Lijuan Hu, Ting Zhao, Wenbing Duan, Jing Wang, Jinsong Jia, Qiang Fu, Ya-Zhen Qin, Hao Jiang, Xiaohui Zhang, Feifei Tang, Yuqian Sun, XiaoDong Mo, Lanping Xu, Yu Wang, Xiaojun Huang, Qian Jiang

Blood (2024) 144 (Supplement 1): 4235.

https://doi.org/10.1182/blood-2024-209768

Published: 2024

Journal Articles

Inhibition of TGF-β in Bone Marrow Endothelial Progenitor Cells Promotes Hematopoietic Recovery in Acute Myeloid Leukemia after Chemotherapy

Zhenkun Wang, Zhi-Wei Zhang, Zhong-Shi Lyu, Tong Xing, Mi Liang, Mengzhu Shen, Chen-Yuan Li, Xin-Yan Zhang, Dan-Dan Chen, Ya-Zhe Wang, Li-Juan Hu, Hao Jiang, Qian Jiang, Yuan Kong, Xiao-Jun Huang

Blood (2024) 144 (Supplement 1): 2684.

https://doi.org/10.1182/blood-2024-201354

Published: 2024

Journal Articles

Immune-Related Signatures Predict Prognosis in Chronic Myeloid Leukemia (CML) Patients Receiving the 3 rd -Generation Tyrosine-Kinase Inhibitors (3G-TKIs)

Xiaoshuai Zhang, Zongru Li, Lu Yu, Mei Bao, Qian Jiang

Blood (2024) 144 (Supplement 1): 3141.

https://doi.org/10.1182/blood-2024-203760

Published: 2024

Journal Articles

High-Risk “Failure” Events Predicting Worse Survival in Patients with Chronic Myeloid Leukemia during Tyrosine Kinase Inhibitor Therapy

Xiaoshuai Zhang, Feiyang Qi, Hanlin Gao, Sen Yang, Qian Jiang

Blood (2024) 144 (Supplement 1): 4531.

https://doi.org/10.1182/blood-2024-205710

Published: 2024

Journal Articles

Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Blood (2024) 144 (Supplement 1): 4529.

https://doi.org/10.1182/blood-2024-203533

Published: 2024

Journal Articles

Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China

Blood (2024) 144 (Supplement 1): 4528.

https://doi.org/10.1182/blood-2024-205232

Published: 2024

Journal Articles

Predictive Models for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Fang Cheng, Yu Wang, Xin Du, Yu Zhu, Jianyu Weng, Na Xu, Yunfan Yang, Jian Huang, Zhenfang Liu, Hongbo Ren, Huifang Zhao, Yajuan Ke, Weiyan Wu, Huanling Zhu, Qian Jiang, Yanli Zhang, Weiming Li

Blood (2024) 144 (Supplement 1): 4540.

https://doi.org/10.1182/blood-2024-202876

Published: 2024

Journal Articles

Validation of Imatinib-Therapy Failure (IMTF) Score in Children with Chronic Myeloid Leukemia in the Chronic Phase

Fangyuan Zheng, Mengyao Yuan, Xiaoshuai Zhang, Qian Jiang

Blood (2024) 144 (Supplement 1): 4534.

https://doi.org/10.1182/blood-2024-206726

Published: 2024

NARROW

The Well Tolerated VA-Based Regimen Bringing to High Quality of Life Did Not Absolutely Inferior to Intensive Chemotherapy in AML Patients with NPM1 Mutation

Bone Marrow Endothelial Progenitor Cells Are Involved in Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Ponatinib 2-Year Efficacy, Safety and Health-Related Quality of Life in Patients with Philadelphia Chromosome-Positive Leukemia: An Open-Label, Multicenter, Phase 2 Clinical Trial in China

Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with CSF3R T618I : A Multi-Centre Retrospective Study

Sex Differences in Disease Characteristics and Outcome in Adults with Acute Myeloid Leukemia from China

Clinical and Molecular Predictors of Response and Survival Following Venetoclax Plus Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China

Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

Genetic Abnormalities Associated with Outcomes in Unfit Patients with Acute Myeloid Leukemia Receiving Less Intensive Therapy in the Real World

Blinatumomab Combined with Venetoclax Increasing the Abundance of CD8 T Cell and NK Cell and Improve the Outcome in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients

Clinical Features and Prognostic Nomogram for Therapy-Related Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

Inhibition of TGF-β in Bone Marrow Endothelial Progenitor Cells Promotes Hematopoietic Recovery in Acute Myeloid Leukemia after Chemotherapy

Immune-Related Signatures Predict Prognosis in Chronic Myeloid Leukemia (CML) Patients Receiving the 3 rd -Generation Tyrosine-Kinase Inhibitors (3G-TKIs)

High-Risk “Failure” Events Predicting Worse Survival in Patients with Chronic Myeloid Leukemia during Tyrosine Kinase Inhibitor Therapy

Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China

Predictive Models for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Validation of Imatinib-Therapy Failure (IMTF) Score in Children with Chronic Myeloid Leukemia in the Chronic Phase

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only